A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

Russell T. Burke, Sarah Meadows, Marc Loriaux, Kevin S. Currie, Scott A. Mitchell, Patricia Maciejewski, Astrid S. Clarke, Julie A. Dipaolo, Brian Druker, Brian J. Lannutti, Stephen Spurgeon

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Agents that target B-cell receptor (BCR) signaling in lymphoid malignancies including idelalisib (GS-1101) and fostamatinib which inhibit the delta isoform of PI3 kinase (PI3Kd) and spleen tyrosine kinase (Syk) respectively have shown significant clinical activity. By disrupting B-cell signaling pathways, idelalisib treatment has been associated with a dramatic lymph node response, but eradication of disease and relapse in high risk disease remain challenges. Targeting the BCR signaling pathway with simultaneous inhibition of PI3Kd and Syk has not yet been reported. We evaluated the pre-clinical activity of idelalisib combined with the novel and selective Syk inhibitor GS-9973 in primary peripheral blood and bone marrow Chronic Lymphocytic Leukemia (CLL) samples. Both PI3Kd and Syk inhibition reduced CLL survival and in combination induced synergistic growth inhibition and further disrupted chemokine signaling at nanomolar concentrations including in bone marrow derived and poor risk samples. Simultaneous targeting of these kinases may significantly increase clinical activity.

Original languageEnglish (US)
Pages (from-to)908-915
Number of pages8
JournalOncotarget
Volume5
Issue number4
StatePublished - 2014

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Bone Marrow
Disease Eradication
Therapeutics
Phosphatidylinositol 3-Kinases
Chemokines
Protein Isoforms
Phosphotransferases
Lymph Nodes
Recurrence
Syk Kinase
6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine
idelalisib
Growth
Neoplasms

Keywords

  • B-cell receptor
  • Chronic lymphocytic leukemia
  • PI3 kinase
  • Signaling pathways
  • Spleen tyrosine kinase

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. / Burke, Russell T.; Meadows, Sarah; Loriaux, Marc; Currie, Kevin S.; Mitchell, Scott A.; Maciejewski, Patricia; Clarke, Astrid S.; Dipaolo, Julie A.; Druker, Brian; Lannutti, Brian J.; Spurgeon, Stephen.

In: Oncotarget, Vol. 5, No. 4, 2014, p. 908-915.

Research output: Contribution to journalArticle

Burke, RT, Meadows, S, Loriaux, M, Currie, KS, Mitchell, SA, Maciejewski, P, Clarke, AS, Dipaolo, JA, Druker, B, Lannutti, BJ & Spurgeon, S 2014, 'A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor', Oncotarget, vol. 5, no. 4, pp. 908-915.
Burke, Russell T. ; Meadows, Sarah ; Loriaux, Marc ; Currie, Kevin S. ; Mitchell, Scott A. ; Maciejewski, Patricia ; Clarke, Astrid S. ; Dipaolo, Julie A. ; Druker, Brian ; Lannutti, Brian J. ; Spurgeon, Stephen. / A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. In: Oncotarget. 2014 ; Vol. 5, No. 4. pp. 908-915.
@article{eedacae5718842859c7c2e588018c0e4,
title = "A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor",
abstract = "Agents that target B-cell receptor (BCR) signaling in lymphoid malignancies including idelalisib (GS-1101) and fostamatinib which inhibit the delta isoform of PI3 kinase (PI3Kd) and spleen tyrosine kinase (Syk) respectively have shown significant clinical activity. By disrupting B-cell signaling pathways, idelalisib treatment has been associated with a dramatic lymph node response, but eradication of disease and relapse in high risk disease remain challenges. Targeting the BCR signaling pathway with simultaneous inhibition of PI3Kd and Syk has not yet been reported. We evaluated the pre-clinical activity of idelalisib combined with the novel and selective Syk inhibitor GS-9973 in primary peripheral blood and bone marrow Chronic Lymphocytic Leukemia (CLL) samples. Both PI3Kd and Syk inhibition reduced CLL survival and in combination induced synergistic growth inhibition and further disrupted chemokine signaling at nanomolar concentrations including in bone marrow derived and poor risk samples. Simultaneous targeting of these kinases may significantly increase clinical activity.",
keywords = "B-cell receptor, Chronic lymphocytic leukemia, PI3 kinase, Signaling pathways, Spleen tyrosine kinase",
author = "Burke, {Russell T.} and Sarah Meadows and Marc Loriaux and Currie, {Kevin S.} and Mitchell, {Scott A.} and Patricia Maciejewski and Clarke, {Astrid S.} and Dipaolo, {Julie A.} and Brian Druker and Lannutti, {Brian J.} and Stephen Spurgeon",
year = "2014",
language = "English (US)",
volume = "5",
pages = "908--915",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "4",

}

TY - JOUR

T1 - A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

AU - Burke, Russell T.

AU - Meadows, Sarah

AU - Loriaux, Marc

AU - Currie, Kevin S.

AU - Mitchell, Scott A.

AU - Maciejewski, Patricia

AU - Clarke, Astrid S.

AU - Dipaolo, Julie A.

AU - Druker, Brian

AU - Lannutti, Brian J.

AU - Spurgeon, Stephen

PY - 2014

Y1 - 2014

N2 - Agents that target B-cell receptor (BCR) signaling in lymphoid malignancies including idelalisib (GS-1101) and fostamatinib which inhibit the delta isoform of PI3 kinase (PI3Kd) and spleen tyrosine kinase (Syk) respectively have shown significant clinical activity. By disrupting B-cell signaling pathways, idelalisib treatment has been associated with a dramatic lymph node response, but eradication of disease and relapse in high risk disease remain challenges. Targeting the BCR signaling pathway with simultaneous inhibition of PI3Kd and Syk has not yet been reported. We evaluated the pre-clinical activity of idelalisib combined with the novel and selective Syk inhibitor GS-9973 in primary peripheral blood and bone marrow Chronic Lymphocytic Leukemia (CLL) samples. Both PI3Kd and Syk inhibition reduced CLL survival and in combination induced synergistic growth inhibition and further disrupted chemokine signaling at nanomolar concentrations including in bone marrow derived and poor risk samples. Simultaneous targeting of these kinases may significantly increase clinical activity.

AB - Agents that target B-cell receptor (BCR) signaling in lymphoid malignancies including idelalisib (GS-1101) and fostamatinib which inhibit the delta isoform of PI3 kinase (PI3Kd) and spleen tyrosine kinase (Syk) respectively have shown significant clinical activity. By disrupting B-cell signaling pathways, idelalisib treatment has been associated with a dramatic lymph node response, but eradication of disease and relapse in high risk disease remain challenges. Targeting the BCR signaling pathway with simultaneous inhibition of PI3Kd and Syk has not yet been reported. We evaluated the pre-clinical activity of idelalisib combined with the novel and selective Syk inhibitor GS-9973 in primary peripheral blood and bone marrow Chronic Lymphocytic Leukemia (CLL) samples. Both PI3Kd and Syk inhibition reduced CLL survival and in combination induced synergistic growth inhibition and further disrupted chemokine signaling at nanomolar concentrations including in bone marrow derived and poor risk samples. Simultaneous targeting of these kinases may significantly increase clinical activity.

KW - B-cell receptor

KW - Chronic lymphocytic leukemia

KW - PI3 kinase

KW - Signaling pathways

KW - Spleen tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=84897451152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897451152&partnerID=8YFLogxK

M3 - Article

C2 - 24659719

AN - SCOPUS:84897451152

VL - 5

SP - 908

EP - 915

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 4

ER -